

amount of 1 ml/guinea pig, the horse serum having been diluted with physiological saline solution in the ratio of 1:10. After 14 days, there are administered the solutions of the substances in the test and physiological solution to the animals kept as control through the parenteral route. Simultaneously, through the intravenous route, 1 ml/guinea pig of undiluted horse serum has been administered as the agent which prompts the anaphylaxis. The percentage of mortality is determined after 12 hours. The results are reported hereinbelow in Table 2.

TABLE 2

| COMPOUND | DOSE,mg/kg | % MORTALITY |
|---------------------------|------------|-------------|
| Physiological Solution | — | 80 |
| 6- α -M-P | 2.5 | 75 |
| 6- α -M-P | 5 | 71 |
| 6- α -M-P | 10 | 65 |
| 6- α -M-P | 15 | 57 |
| 6- α -M-P + L-A.M. | 2.5 + 1.3 | 53 |
| 6- α -M-P + L-A.M. | 5 + 2.6 | 38 |
| 6- α -M-P + L-A.M. | 10 + 3.9 | 21 |
| 6- α -M-P + L-A.M. | 15 + 10 | 12 |

The meaning of the symbols and abbreviations are explained under Table 1.

What is claimed is:

1. A pharmaceutical composition consisting essentially of a salt of 6- α -methyl-prednisolone-21-hemisuccinate and a L-arginine ester in the form of the hydrochloride salt.

2. A pharmaceutical composition according to claim 1 wherein said salt of 6- α -methyl-prednisolone-21-hemisuccinate and said L-arginine ester are in molar ratio of 1:1.

3. The method of protecting a living subject against shocks which consists of administering to said subject through the parenteral route an effective amount of a composition containing a salt of 6- α -methyl-prednisolone-21-hemisuccinate and the methyl ester of L-arginine in the form of the hydrochloride salt.

4. The method according to claim 3 wherein said composition contains said salt of 6- α -methyl-prednisolone-21-hemisuccinate and L-arginine methyl ester in the molar ratio of 1:1.

* * * * *

25

30

35

40

45

50

55

60

65